1. Survival and prognostic factors of salivary gland malignant mixed tumor-not otherwise specified: A population-based analysis.
- Author
-
Soffer JM, Nassif SJ, Von Plato M, Chisholm J, and O'Leary MA
- Subjects
- Adenoma, Pleomorphic pathology, Adenoma, Pleomorphic therapy, Female, Humans, Lymph Nodes pathology, Male, Middle Aged, Mixed Tumor, Malignant epidemiology, Mixed Tumor, Malignant pathology, Mixed Tumor, Malignant therapy, Neoplasm Staging, Prognosis, Retrospective Studies, SEER Program, Salivary Gland Neoplasms epidemiology, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms therapy, Salivary Glands pathology, Survival Rate, Adenoma, Pleomorphic epidemiology, Adenoma, Pleomorphic mortality, Mixed Tumor, Malignant mortality, Salivary Gland Neoplasms mortality
- Abstract
Objective: Malignant mixed tumors of the salivary gland are a group of neoplasms comprised of carcinoma-ex-pleomorphic adenoma, carcinosarcoma, and metastasizing pleomorphic adenoma. An alternative classification, malignant mixed tumor-not otherwise (MMT-NOS), is a diagnosis of exclusion for neoplasms that do not fit the previous histologically profiled subtypes. The objective was to provide a comprehensive assessment of MMT-NOS and determine prognostic factors., Methods: This retrospective cohort study queried the Surveillance, Epidemiology, and End Results database for patient and tumor characteristics of US patients with MMT-NOS of the major salivary glands from 1973 to 2016. Kaplan-Meier and Cox regression analysis were performed to determine 5-year survival and prognostic factors., Results: 434 patients were identified with a mean age at diagnosis of 61.5 years. The majority of neoplasms were high grade and stage (70.8% grade III/IV; 63.8% stage III/IV). Extraparenchymal extension (40.6%) and lymph node involvement (28.5%) were common; distant metastases (2.4%) were rare. Treatment included surgery (93.0%), radiation (51.6%), and chemotherapy (10.4%). Facial nerve sacrifice was common (50.8%). Median survival was 66.5 months. 5-year overall and disease-specific survival were 65.7% and 83.0%, respectively. In multivariate analysis, nodal involvement (HR 7.0; P < 0.001), surgery-radiation-chemotherapy (HR 6.1; P = 0.02), extraparenchymal extension (HR 2.50; P = 0.04), and tumor size >4 cm (HR 1.3; P = 0.03) were prognostic factors., Conclusion: Despite high stage and grade at diagnosis, MMT-NOS portends a good 5-year prognosis and low rate of distant metastasis. Prognostic factors were nodal involvement, tumor size, and extraparenchymal extension., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF